Preliminary Antitumor Activity, Safety and Tolerability of Tislelizumab in Combination With Lenvatinib for Hepatocellular Carcinoma – Beigene

⟵ Back to Search Results

Preliminary Antitumor Activity, Safety and Tolerability of Tislelizumab in Combination With Lenvatinib for Hepatocellular Carcinoma

Beigene Study ID

BGB-A317-211

ClinicalTrials.gov ID

NCT04401800

China Drug Trials ID

CTR20200972

Study Overview

Sex: All

Age: 18 Years to 70 Years (Adult, Older Adult)

No Study Documents

Locations

Study Overview

Sex: All

Age: 18 Years to 70 Years (Adult, Older Adult)

No Study Documents